Copolymer 1 inhibits experimental autoimmune uveoretinitis
- 1 January 2000
- journal article
- research article
- Published by Elsevier in Journal of Neuroimmunology
- Vol. 103 (2) , 189-194
- https://doi.org/10.1016/s0165-5728(99)00239-8
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- The development of Cop 1 (Copaxone®), and innovative drug for the treatment of multiple sclerosis: personal reflectionsImmunology Letters, 1996
- Copolymer 1 inhibits chronic relapsing experimental allergic encephalomyelitis induced by proteolipid protein (PLP) peptides in mice and interferes with PLP-specific T cell responsesJournal of Neuroimmunology, 1996
- T cell immunity to myelin basic protein induces anterior uveitis in Lewis ratsJournal of Neuroimmunology, 1994
- Expanded clinical trials of treatments for multiple sclerosis: Copolymer 1 (COP-1) treatment investigational new drug (IND) programAnnals of Neurology, 1994
- FUNCTIONAL PROPERTIES OF INTERPHOTORECEPTOR RETINOID‐BINDING PROTEIN*Photochemistry and Photobiology, 1991
- Pathology of experimental autoimmune uveoretinitis in miceJournal of Autoimmunity, 1990
- Immune responses to peptides derived from the retinal protein IRBP: Immunopathogenic determinants are not necessarily immunodominantClinical Immunology and Immunopathology, 1989
- A Pilot Trial of Cop 1 in Exacerbating–Remitting Multiple SclerosisNew England Journal of Medicine, 1987
- Suppression of experimental allergic encephalomyelitis in rhesus monkeys by a synthetic basic copolymerClinical Immunology and Immunopathology, 1974
- Suppression of experimental allergic encephalomyelitis by a synthetic polypeptideEuropean Journal of Immunology, 1971